Degraded elastin (elastin-derived peptides) (EDPs)

Degraded elastin, also known as elastin-derived peptides (EDPs) or elastokines, arises from the proteolytic breakdown of mature elastin fibers in the extracellular matrix by enzymes such as matrix metalloproteinases (MMP-2, MMP-7, MMP-9, MMP-12) and elastases, often triggered by inflammation, oxidative stress, or aging.[1][2] These fragments retain bioactivity, promoting proinflammatory responses including neutrophil chemotaxis, T-helper type 1 lymphocyte polarization, and secretion of cytokines and proteases from fibroblasts and vascular smooth muscle cells.[1] In disease contexts, EDPs contribute to atherosclerosis by oxidizing low-density lipoproteins and fostering vascular calcification, while also driving arterial stiffness, aneurysm formation, and plaque instability through excessive matrix remodeling.[1] Elevated serum EDPs serve as biomarkers reflecting the extent of elastin degradation in cardiovascular pathologies.[1] Unlike intact elastin, which provides tissue elasticity and recoil, degraded forms exacerbate fibrosis and impair vascular compliance, with no established drugs directly targeting them therapeutically; instead, strategies focus on upstream inhibitors like MMP antagonists or TNF-α blockers to curb production.[1] Overall, degraded elastin signals pathological ECM turnover rather than serving as a conventional druggable target.[1][2]

Other names

Elastokineselastin fragmentselastin degradation products